Down Sizing Strategy (HANGZHOU Solution) vs Standard Sizing Strategy TAVR in Bicuspid Aortic Stenosis (Type 0)
A legfontosabb adatok
- Ki végzi
- Second Affiliated Hospital, Zhejiang University, School of Medicine
- Hol
- Kína15 helyszín, 1 országbanVálassz országot a helyszínekhez
- Azonosító
- Állapot
- Fut, nem toboroz
- Résztvevők
- 206 fő, tervezett
- Kezdés
- 2022. júl. 20.
- Várható befejezés
- 2031. máj. 30.
- A vizsgálat típusa
- Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
- A vizsgált kezelések
- TAVR for BAV Using Down Sizing with the Evolut Pro platform
- TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform
- A regiszteradat frissítve
- 2026. október 21.
Ki vehet részt
- Életkor
- 60 év felett
- Nem
- Nők és férfiak
- Egészséges önkéntesek
- Nem vehetnek részt
A regiszter feltételei, szó szerint
Mind a 29 feltétel megnézéseKevesebb
Ki vehet részt
- Age ≥ 65 years
- Age <65 years and age ≥ 60 years with high surgical risk after combing STS Risk Estimate (≥ 8%), Katz activities of Daily Living, major Organ System Dysfunction and Procedure-Specific Impediment
- Severe, bicuspid aortic stenosis: Mean gradient ≥40 mmHg OR Maximal aortic valve velocity ≥4.0 m/sec OR Aortic valve area ≤1.0 cm2 (or aortic valve area index of ≤0.6 cm2/m2); if SVi <35mL/m2, low-dose dobutamine stress echocardiography is required
- NYHA classification ≥ II
- Type 0 (Sievers classification) by MDCT
- Perimeter-derived annulus diameter ranges from 20.0 mm to 26.0 mm
- Candidate for Transfemoral TAVR
- The study patient has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the Institutional Review Board (IRB)/Ethics Committee (EC) of the respective clinical site
Ki nem vehet részt
- Any Emergent surgery required before TAVR procedure
- Currently participating in an investigational drug or another device study (excluding registries)
- Severe mitral stenosis amenable to surgical replacement or repair
- Previous pacemaker implantation
- Evidence of an acute myocardial infarction ≤ 1 month (30 days) before the intended treatment [(defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥ twice normal in the presence of MB elevation and/or troponin level elevation (WHO definition)]
- Stroke or transient ischemic attack (TIA) within 3 months (90 days) of the procedure
- Estimated life expectancy < 12 months (365 days) due to carcinomas, chronic liver disease, chronic renal disease or chronic end stage pulmonary disease
- A known hypersensitivity or contraindication to any of the following that cannot be adequately medicated:aspirin or heparin (HIT/HITTS) and bivalirudin; clopidogrel; Nitinol (titanium or nickel); contrast media
- Gastrointestinal (GI) bleeding that would preclude anticoagulation
- Severe dementia (resulting in either inability to provide informed consent for the study/procedure, prevents independent lifestyle outside of a chronic care facility, or will fundamentally complicate rehabilitation from the procedure or compliance with follow-up visits)
- Other medical, social, or psychological conditions that in the opinion of the investigator precludes the subject from appropriate consent or adherence to the protocol required follow-up exams
- Significant aortic disease, including marked tortuosity (hyperacute bend), aortic arch atheroma [especially if thick (> 5 mm), protruding or ulcerated] or narrowing (especially with calcification and surface irregularities) of the abdominal or thoracic aorta, severe"unfolding" and horizontal aorta(Annular Angulation>70°)
- Any contra-indication for Self-expanding bioprosthetic aortic valve deployment Leukopenia (WBC < 3000 cell/mL), acute anemia (Hgb < 9 g/dL), Thrombocytopenia (Plt< 50,000 cell/mL)
- Active sepsis, including active bacterial endocarditis with or without treatment
- Subject refuses a blood transfusion
- Hypertrophic cardiomyopathy (HCM with myocardium more than 1.5cm without an identifiable cause) with obstruction (HOCM)
- Echocardiographic evidence of intracardiac mass, thrombus or vegetation
- Aortic valve type cannot be determined (Sievers classification)
- Ascending aorta diameter > 50 mm
- Aortic or iliofemoral vessel characteristics that would preclude safe placement of the introducer sheath
- Patient is considered high risk for TAVR by CT corelab, including coronary obstruction, annular rupture and other severe TAVR-Related complications
Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.
Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.
A vizsgálatról
Mit akar kideríteni a vizsgálat
To compare down sizing strategy versus annular sizing strategy technique (control group) in Type 0 bicuspid aortic stenosis (AS) patients undergoing transcatheter aortic valve replacement (TAVR) with self-expanding valves (SEVs): a randomized superiority trial
A vizsgálat 2 csoportja
- TAVR with down sizing strategyA vizsgált kezelés
Balloon sizing will be used during procedural. Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm. Waist sign with less than mild contrast regurgitation: Evolut PRO Valve one size smaller than manufacturer recommendation and Target implant depth 0-3mm. No waist sign and/or contrast regurgitation or unable to finish supra-annular sizing: Evolut PRO annular sizing (per manufacturer recommendation) with implant depth 0-3mm.
Kezelés: TAVR for BAV Using Down Sizing with the Evolut Pro platform
- TAVR with standard sizing strategyMár használt kezelés, összehasonlításként
Pre-dilation with balloon size just below the annular size. 20mm for annular size of 20-23mm. 23mm for annular size 23-26mm. The prosthesis size of Evolut PRO will be chosen based on manufacturer recommendation. The target implant depth will be 0-3mm.
Kezelés: TAVR for BAV Using Traditional Sizing strategy with the Evolut Pro platform
Adatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- Transcatheter Aortic Valve Replacement For Patients With Bicuspid Aortic Stenosis (Type 0) Using Down Sizing Strategy Compared With Standard Sizing Strategy (HANGZHOU Solution): A Prospective, Multicenter, Randomized Controlled Trial
- Publikációk
- A regiszteradat frissítve
- 2026. október 21.